Precision medicine and drug optimization in adult inflammatory bowel disease patients.

Authors:
Vieujean S; Louis E.

Journal:
Therap Adv Gastroenterol

Publication Year: 2023

DOI:
10.1177/17562848231173331

PMCID:
PMC10184262

PMID:
37197397

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Therap Adv Gastroenterol

Abbreviation: Therap Adv Gastroenterol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology & Hepatology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Add-on immunosuppressive therapy may benefit selected patients with primary biliary cholangitis and…
Li M; Chen S; Li S and 13 more (2024) - Transparency Score: 3/6
Attitudes, perceptions and barriers in implementing therapeutic drug monitoring for anti-TNFs in in…
Nigam GB; Chatten K; Sharara A and 6 more (2024) - Transparency Score: 4/6
Chemotherapy combined with targeted therapy and immunotherapy is an option in advanced biliary trac…
Ge P; Wu Y. (2024) - Transparency Score: 3/6
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with u…
Calafat M; Torres P; Tosca-Cuquerella J and 56 more (2024) - Transparency Score: 3/6
Echoendoscopic ultrasound pancreatic adenocarcinoma diagnosis and theranostic approach: should <i>K…
Béchade D; Palmieri LJ; Bonhomme B and 7 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"S Vieujean received speaker’s fees from Janssen, Takeda, Ferring and Abbvie.: E Louis received research grant: Janssen, Pfizer, Ferring, Falk, Abbvie and Takeda; educational grant: AbbVie, Janssen, Fresenius-Kabi and Takeda; speaker fees: Abbvie, Falk, Ferring, Janssen, Pfizer, Galapagos and Takeda; advisory board: Abbvie, Celgene, Ferring, Janssen, BMS, Pfizer, and Takeda, Galapagos, Gilead, Arena, Elli Lilly; consultant: Abbvie"

Evidence found in paper:

"Funding: The authors received no financial support for the research, authorship, and/or publication of this article."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025